September 16th 2024
Your daily dose of the clinical news you may have missed.
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
September 9th 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
Treat Obesity as a Risk Factor, not a Prerequisite for Pediatric T2D Screening
About one-quarter of children with T2D are not obese, according to a meta-analysis, making comprehensive screening essential in the population.
FDA Clears Dexcom G7 CGM System for Persons with T1D and T2D
The Dexcom G7 continuous glucose monitoring system provides an overall MARD of 8.2%, the highest of any FDA-cleared CGM, the company says.
Empagliflozin Reduces HbA1c, FPG in Pediatric Population with Type 2 Diabetes
Empagliflozin is the first SGLT-2 inhibitor to demonstrate a statistically significant reduction in HbA1c in children and adolescents with type 2 diabetes.
Butryate Supplementation May Support Pediatric Obesity Treatment
Findings from a new study suggest that supplementing standard care for obesity with butyrate helped reduce BMI, improve glucose metabolism, and reduce inflammation markers.
Diabetes and Obesity: Why Obesity Treatment Should Come First
An obesity specialist explains why clinicians should start at the root cause when managing patients with type 2 diabetes and obesity.
Doubling Levonorgestrel Dose Fails to Prevent Pregnancy in Women with Obesity
The "Plan B" emergency contraceptive at 2 times the normal dose was not more effective in study participants with BMI >30.
FDA Approves Teplizumab, First Drug Indicated to Prevent Type 1 Diabetes
Teplizumab, an anti-CD3 monoclonal antibody, delayed the median onset of stage 3 T1D by approximately 2 years compared to placebo in a pivotal clinical trial.
The Promise of Precision Medicine for Obesity: It Should be Simple
Ordering an obesity phenotype should be as simple and routine as ordering an HbA1c or a lipid panel, says obesity expert Andres Acosta, MD, PhD.
Obesity Phenotypes Explain What Drives the Disease and How to Target Intervention: Expert Interview
Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.
AACE President Discusses New Guideline Recommendations for Cardiorenal Protective Therapy in T2D
Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.
Management of Type 2 Diabetes Complications, Comorbidities Focus of AACE 2022 Guideline Update
AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.
Obesity Research Roundup for Primary Care: 5 Studies At-a-Glance from ObesityWeek® 2022
Semaglutide yields "amazing" weight loss in adolescents, phenotype-tailored lifestyle approach leads to greater weight loss vs standard methods, and more.
Sotagliflozin Cuts Risk by >50% for Heart Failure Readmission, CV Death in Phase 3 SOLOIST-WHF Trial
In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.
Empagliflozin Reduced Risk of Renal Disease Progression, CV Death Across CKD Spectrum in EMPA-KIDNEY
Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.
AACE President Sethu Reddy, MD, Highlights Updated 2022 Diabetes Guidelines for Primary Care
Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.
Practice-related Factors in Primary Care May Limit Weight Management Services Offered
ObesityWeek® 2022. Primary care clinicians report providing on average just 70% of a wide range of clinical weight management services, according to a new survey.
Investigational Glucagon Receptor/GLP-1 Receptor Dual Agonist Bests Semaglutide for Weight Loss in T2D Patients
ObesityWeek® 2022. Coagonism of the glucagon and GLP-1 receptors appears to result in greater weight loss than GLP-1 receptor agonism alone, study suggests.
Tirzepatide Led to Clinically Meaningful Improvements in Body Composition in Adults with Obesity/Overweight
ObesityWeek 2022: Tirzepatide-induced weight reduction was associated with body composition improvements in adults with obesity/overweight, found analysis of SURMOUNT-1.
Daily Dose: Low-carb Diet May Help Improve Untreated HbA1c
Your daily dose of clinical news you may have missed.
Low-carbohydrate Diet Could Help Improve Untreated HbA1c of 6.0% to 6.9%
In patients with prediabetes and untreated type 2 diabetes, a reduced carbohydrate diet improved HbA1c and other metabolic markers vs a usual diet.
Daily Dose: Oral Superabsorbent Hydrogel Cuts Risk for Type 2 Diabetes
The Daily Dose: Insulin Rationing
Your daily dose of clinical news from Patient Care Online.
Drop in Vitamin D Implies Increased Cardiovascular Risk in T2D, According to New Research
CMHC 2022: A decrease in vitamin D levels is associated with increased cardiovascular risk in patients with type 2 diabetes, according to new study.
Insulin Rationing Common Among Adults with Diabetes, Likely to Avoid High Cost
Analysis of national health data found that 16.5% of all adult insulin users skipped doses in the past year.
Weight Loss is Essential to Optimize Type 2 Diabetes Treatment Management
Weight loss of at least 5% to 10% for persons with T2D is realistic and essential, says Nisa Maruthur, MD, MHS, coauthor of the new ADA/EASD consensus report.
ADA/EASD Consensus Report on T2D Management: Coauthor Talks Take-homes for Primary Care
Nisa Maruthur, MD, MHS, a primary care physician and consensus report coauthor, discusses elements of the most effective care for patients with type 2 diabetes (T2D).
4 New Drugs Approved for Primary Care: Q3 2022
Novel NMDA receptor antagonist approved for the treatment of major depressive disorder, first topical PDE4i approved for plaque psoriasis, and more.
FreeStyle Libre 3 CGM Linked with Reduced Hospital Admissions in Patients with T2D
Hospital admissions among patients with T2D taking basal insulin only were reduced by 67% one year after beginning treatment with the CGM system.
Specific Blood Pressure Thresholds Not Needed When Selecting Patients with T2D for Antihypertensive Treatment, Suggests New Research
Blood pressure-lowering therapy reduced the risk of major CV events in persons with and without type 2 diabetes, according to an individual participant-level data meta-analysis.
Patients with Diabetes Face Higher Risk for Left-sided Valvular Stenotic Lesions
A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.